senseibio.com (SNSE) Long-Term Debt to Capital Ratio

Sensei Biotherapeutics Inc - graphic logo of issuer SNSE

The long-term debt financial leverage ratio demonstrates the liability structure of Sensei Biotherapeutics (SNSE), where the value of 0.01 characterizes this level. The company's revenues are based on the development of vaccines for immune activation and fund support. Growth relies on alliances with laboratories and the acquisition of protein platforms. Business stability is ensured by cyclical resilience and the successful completion of clinical trials.

Long-Term Debt to Equity: Sensei Biotherapeutics Inc (SNSE) for 07/04/2022 - 06/16/2026
Brand item of Sensei Biotherapeutics, Inc.

This ratio compares the volume of long-term liabilities to the company's equity. It determines the extent of the business's dependence on external borrowing over a long-term horizon. By analyzing the long-term debt-to-equity trend, an investor assesses financial stability and bankruptcy risk. Low leverage is critically important for Sensei Biotherapeutics (SNSE). The use of third-party manufacturing sites (CMO) minimizes the need for capital loans to construct plants.

Competing companies

Long-Term Liabilities to Capital ImmunityBio Inc IBRX|Long-Term Debt to Equity Immunocore PLC (IMCR)|Janux Corp - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RCUS (Arcus Biosciences, Inc.)|ZYME - Long-Term Debt to Equity Ratio|TNGX - Long-Term Debt to Equity|Long-Term Liabilities to Capital Iovance Biotherapeutics Inc|Immatics Corp (IMTX) - Long-Term Debt to Equity|XNCR (Xencor Inc.) - Long-Term Debt to Equity|Long-Term Debt to Equity Compass Therapeutics|Long-Term Liabilities to Capital replimune.com REPL|Long-Term Debt to Capital LYEL|Innate Pharma SA (IPHA) - Long-Term Indebtedness to Equity|Pyxis Oncology - Long-Term Debt to Equity Ratio|Compugen Ltd (CGEN) - Long-Term Liabilities to Capital|IOBT: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient STRO (sutrobio.com)|INKT: Long-Term Debt to Capital|HOWL - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Immix Biopharma Inc.|Long-Term Debt to Equity Ratio alxoncology.com (ALXO)|Long-Term Debt to Equity Cue Biopharma (CUE)|Long-Term Debt to Equity Ratio pdsbiotech.com PDSB|Sonnet BioTherapeutics Holdings - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital MAIA Biotech MAIA|LIMN - Long-Term Debt to Equity|LVTX (LAVA Therapeutics N.V.) - Long-Term Debt to Capital Ratio|NextCure, Inc. (NXTC) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Leap Therapeutics (LPTX)|Long-Term Debt to Equity Ratio INTS|TOVX - Long-Term Indebtedness to Equity|Long-Term Debt to Equity Ratio GRTS (Gritstone bio, Inc.)|Long-Term Loans to Capital Ratio KA|Long-Term Debt to Capital NEXI (NexImmune, Inc.)|Long-Term Debt to Capital Coefficient TSBX|Vaccinex - Long-Term Debt to Capital|Long-Term Liabilities to Capital Harpoon Therapeutics Inc